GHK-Cu Research History: From 1973 Plasma Discovery to Gene Data

GHK-Cu has a longer paper trail than almost any other peptide sold for research. It was pulled out of human blood plasma in 1973, had its sequence confirmed in 1977, and by 2010 had turned up in a Broad Institute gene database as a compound that reverses disease signatures. The record is real, but it is also narrower than the claims built on top of it.

Where GHK-Cu came from: Loren Pickart and a liver experiment

The story starts with a biochemist, Loren Pickart, working at the University of California in the early 1970s. He noticed that plasma from young people made liver tissue taken from older people produce proteins more typical of young tissue, and he set out to find the factor responsible.

His 1973 doctoral work isolated the activity from the albumin fraction of human serum. The paper is cited in his later reviews as "A Tripeptide from Human Serum Which Enhances the Growth of Neoplastic Hepatocytes and the Survival of Normal Hepatocytes" (Pickart, Vasquez-Soltero and Margolina, BioMed Research International, 2015).

The sequence came later. A 1977 note by Schlesinger, Pickart and Thaler in Experientia identified the factor as glycyl-histidyl-lysine, three amino acids and nothing more. The ghk-cu sold to laboratories today is that same tripeptide, supplied with its copper.

The copper connection, Nature 1980

The copper part of the name was not an afterthought. When Pickart's group isolated the peptide, it co-purified with roughly equimolar copper and about one fifth as much iron, and the biggest effects on cultured liver cancer cells came when the peptide was added together with the metals.

In a 1980 Nature paper the group proposed that GHK acts as a copper transport factor. They pointed to a resemblance between the tripeptide and the copper-binding sites on albumin and alpha-fetoprotein, where copper sits on a histidine next to a basic residue (Pickart et al., Nature, 1980).

A year later Lau and Sarkar measured the binding directly. Using potentiometric titration and equilibrium dialysis, they showed GHK could compete with albumin for copper at pH 7.5: with equal amounts of albumin and peptide, about 42% of the copper ended up on the peptide (Biochemical Journal, 1981).

That is the chemistry a researcher is buying when they order copper peptide ghk-cu. The lysine side chain, the histidine ring and the free amino group hold the copper tightly enough that the complex survives in plasma.

The 1980s: collagen and the wound signal hypothesis

The most cited single experiment is from Reims. François-Xavier Maquart and colleagues added GHK-Cu to cultured fibroblasts and measured collagen synthesis. Stimulation began between 10 to the minus 12 and 10 to the minus 11 molar, peaked at 10 to the minus 9 molar, and was independent of any change in cell number (Maquart et al., FEBS Letters, 1988).

The same paper noticed something neat. The GHK triplet sits inside the alpha 2(I) chain of type I collagen, so when proteases chew up damaged collagen at a wound, they may release GHK on the spot. Maquart proposed it as an early signal for repair.

Follow-up work from the same group through the 1990s found GHK-Cu also stimulated sulfated glycosaminoglycans, the proteoglycan decorin, and matrix metalloproteinase-2, as summarised in the 2015 review. For a researcher who wants to buy ghk-cu to repeat or extend that fibroblast work, these are the baseline papers.

2010 to 2012: the Connectivity Map finds GHK twice

The second act of the research record has nothing to do with Pickart. The Broad Institute of MIT and Harvard built the Connectivity Map, a public library of how cultured human cells change their gene expression when exposed to known compounds. Researchers can feed in a disease signature and ask which compounds push it the other way.

In 2010 a Singapore group led by Hong profiled 82 colorectal cancer patients and controls on Affymetrix arrays and derived a 54-gene signature for metastasis-prone early-stage disease. When they queried the Connectivity Map with a subset of those genes, two compounds came back as reversing the pattern: Gly-His-Lys and the plant alkaloid securinine (Hong et al., Clinical and Experimental Metastasis, 2010).

Two years later a Boston University team did the same thing for emphysema. They profiled 64 lung tissue samples, eight regions from each of eight lungs from smokers with COPD, and found 127 genes tracking with how destroyed each region was. The Connectivity Map again pointed to GHK as a compound that could reverse the signature and switch on TGF-beta pathway genes (Campbell et al., Genome Medicine, 2012).

Both findings were in cells and databases, not patients. The Genome Medicine authors said so themselves, calling for further studies on mechanism and on whether reversing the signature changes disease progression.

Pickart's gene reviews: 31.2% of genes and what that means

Pickart and Anna Margolina took the Connectivity Map data and ran their own counts. In a 2015 paper in the MDPI journal Cosmetics they reported that GHK produced a 50% or greater change in expression in 31.2% of human genes.

Their 2018 review in the International Journal of Molecular Sciences tabulated the figures: at the 50 to 99% change band, 1,569 genes went up and 583 went down, with smaller numbers at higher fold changes. Overall 59% of affected genes increased and 41% decreased (Pickart and Margolina, IJMS, 2018).

Those numbers are striking but need reading carefully. A compound that shifts a third of the genome in a cultured cell line is a compound with broad effects, not a compound with proven benefits. Both reviews are written by the peptide's discoverer, whose 2015 paper gives a company address at Skin Biology in Bellevue, Washington, which readers should weigh.

They are also why a ghk-cu uk order today is as likely to come from a genomics lab as from a skin lab.

What has been shown, and what has not

It helps to separate the record into tiers. The strongest evidence is in vitro: copper binding, fibroblast collagen synthesis at nanomolar concentrations, and gene-expression changes in cultured cells. These have been reproduced by independent groups in France, Singapore and Boston.

The middle tier is topical human studies for wounds and photoaged skin, most of them small and many funded by the cosmetics industry. Those are covered in the companion post on GHK-Cu and collagen in skin studies.

The bottom tier is everything else now circulating online. In September 2026 NPR reported on the shift from creams to self-injection of copper peptides and stated plainly that there is no data from published human studies showing that practice is safe or effective (NPR, 2026). Warren Ladiges of the University of Washington, who has studied the peptide in mice for years, told NPR he would not inject himself without knowing what it does.

• Shown: high-affinity copper binding, measured in 1981
• Shown: collagen synthesis in cultured fibroblasts, 1988
• Shown: reversal of disease gene signatures in cell databases, 2010 and 2012
• Not shown: any outcome in a randomised human trial of systemic GHK-Cu

Nothing here changes what the product is. LynxLab stocks GHK-Cu for research use in 50mg and 100mg vials from £23.99, tested to 99% purity with the lab report on the product page. At the 10 nanomolar concentration Campbell's group used, a single ghk-cu 100mg vial holds enough peptide for a very large number of culture plates.

Regulatory status in late 2026

GHK-Cu is not a licensed medicine anywhere. In cosmetics it appears on ingredient lists as copper tripeptide-1, and in laboratories it is a research chemical. Ladiges told NPR that because the molecule occurs naturally it is hard to patent, so no company is likely to fund the trials needed for drug approval.

In the United States the FDA has placed it on the agenda of its Pharmacy Compounding Advisory Committee, which will meet before the end of February 2027 to discuss whether GHK-Cu should join the 503A bulks list that compounding pharmacies may draw on (FDA, 2026). The committee's recommendations are non-binding.

In the UK there is no equivalent process. Buying ghk cu is legal for research purposes, and the responsibility for what happens to it sits with the buyer. Independent lab reports matter more, not less, when a regulator has not looked at the material. Anyone handling the lyophilised powder should also read the practical notes on why GHK-Cu is blue and how it is stored.

Frequently asked questions

Who discovered GHK-Cu?

Loren Pickart isolated the activity from the albumin fraction of human serum at the University of California in 1973, while studying why young plasma rejuvenated old liver tissue. The sequence glycyl-histidyl-lysine was confirmed in a 1977 paper by Schlesinger, Pickart and Thaler. The copper transport hypothesis followed in Nature in 1980.

Does GHK-Cu really affect 4,000 genes?

The figure comes from Pickart's analysis of the Broad Institute Connectivity Map, where GHK changed expression of about 31.2% of genes by 50% or more in cultured cells. That is a database measurement in a cell line, not an effect demonstrated in a person. Independent groups found GHK in the same database as a reverser of colon cancer and emphysema signatures.

Has GHK-Cu been tested in human clinical trials?

Only topically, for diabetic ulcers in 1994 and for photoaged facial skin in several 12-week cosmetic studies. There are no published randomised trials of GHK-Cu given systemically to people, as NPR confirmed in September 2026. The FDA advisory committee review scheduled for early 2027 concerns compounding, not approval.

Is GHK-Cu legal in the UK?

Yes, for research. It is not a controlled substance and not a licensed medicine, and it is widely sold as a cosmetic ingredient under the name copper tripeptide-1. UK research suppliers sell the lyophilised peptide with batch testing for laboratory use.

Sources

• GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration, BioMed Research International, 2015
• Growth-modulating plasma tripeptide may function by facilitating copper uptake into cells, Nature, 1980
• Stimulation of collagen synthesis in fibroblast cultures by GHK-Cu, FEBS Letters, 1988
• A metastasis-prone signature for early-stage colorectal cancer, Clinical and Experimental Metastasis, 2010
• A gene expression signature of emphysema and its reversal by the tripeptide GHK, Genome Medicine, 2012
• Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data, IJMS, 2018
• People are injecting copper peptides ahead of the science, NPR, 2026
• Meeting of the Pharmacy Compounding Advisory Committee, FDA, 2026